4-[4-(3,5-Dichloro-phenyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-2-hydroxy-butan-1-one | 95217-35-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[4-(3,5-Dichloro-phenyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-2-hydroxy-butan-1-one
• 英文别名: 4-[4-(3,5-dichlorophenyl)piperazin-1-yl]-1-(4-fluorophenyl)-2-hydroxybutan-1-one
• CAS: 95217-35-9
• 化学式: C₂₀H₂₁Cl₂FN₂O₂
• 分子量: 411.303
• InChiKey: XLBRCIOLMGTRDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.89
• 重原子数：
  27.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  43.78
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  4-[4-(3,5-Dichloro-phenyl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-2-hydroxy-butan-1-one 在 吡啶 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.25h， 生成 3-Acetyl-5-{2-[4-(3,5-dichloro-phenyl)-piperazin-1-yl]-ethyl}-4-(4-fluoro-phenyl)-3H-oxazol-2-one
  参考文献：
  名称：

  5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity

  摘要：

  A series of new 4-aryl-5-[omega-(4-aryl-1-piperazinyl)alkyl]-2(3H)- oxazolones was synthesized and tested for neuroleptic activity in mice and rats. Several compounds exhibited interesting neuroleptic activity with very low liability to the extrapyramidal side effects. In particular the activity of 4-(4-fluorophenyl)-5-[2-[4-(3,5-dichlorophenyl)-1- piperazinyl]ethyl]-2(3H)-oxazolone (14) was greater than that of butropipazone and fluanisone, while of the same order of that of chlorpromazine; however, the product showed a longer lasting activity and minor ability to produce catalepsy as compared with the reference drugs.

  DOI：

  10.1021/jm00130a003

文献信息

• N-Phenylpiperazine derivatives with hypocholesterolemic activity
  作者：Giuseppe Cascio、Elso Manghisi、Roberto Porta、Giancarlo Fregnan

  DOI：10.1021/jm00383a021

  日期：1985.6

  A series of new 4-(4-phenyl-1-piperazinyl)-1-(4-fluorophenyl)-2-(acyloxy)-1-butanones and 4-aryl-5-[omega-(4-aryl-1-piperazinyl)alkyl]-1,3-dioxol-2-ones were synthesized and tested preliminarily for hypolipemic activity. Plasma cholesterol-lowering activity in normal rats was found especially in several dioxolones, two of the most active compounds (6 and 8) being more potent than clofibrate. 4-(4-

  一系列新的4-（4-苯基-1-哌嗪基）-1-（4-氟苯基）-2-（酰氧基）-1-丁酮和4-芳基-5-ω-（4-芳基-1-合成哌嗪基）烷基] -1，3-二氧杂-2-酮并初步测试其降血脂活性。在正常大鼠中发现降低血浆胆固醇的活性，尤其是在几种二氧戊环酮中，其中两种活性最高的化合物（6和8）比氯贝特更有效。已选择4-（4-氯苯基）-5- [2-（4-苯基-1-哌嗪基）乙基] -1,3-二氧杂-2--2-（8，LR-19,731）进行临床试验。
• CASCIO, GIUSEPPE;MANGHISI, ELSO;FREGNAN, GIANCARLO, J. MED. CHEM., 32,(1989) N0, C. 2241-2247
  作者：CASCIO, GIUSEPPE、MANGHISI, ELSO、FREGNAN, GIANCARLO

  DOI：——

  日期：——
• CASCIO, G.;MANGHISI, E.;PORTA, R.;FREGNAN, G., J. MED. CHEM., 1985, 28, N 6, 815-818
  作者：CASCIO, G.、MANGHISI, E.、PORTA, R.、FREGNAN, G.

  DOI：——

  日期：——